109 results
8-K
EX-99.1
ALGS
Aligos Therapeutics Inc
7 May 24
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
4:05pm
due to a decrease in employee related costs, partially offset by an increase in third party expenses. Total R&D stock-based compensation expense
PRE 14A
ALGS
Aligos Therapeutics Inc
16 Apr 24
Preliminary proxy
5:27pm
Units
Reserved
for Future
Issuance
Pursuant
to New
Grants
Under the
2020 Incentive
Award Plan
Reserved
for Future
Issuance
Pursuant
to 2020
Employee …
Issuance
Pursuant
to 2020
Employee
Stock
Purchase
Plan
Pre-Reverse Stock Split
Post-Reverse Stock Split 1 for 5
Post-Reverse Stock Split 1 for 15
S-8
ALGS
Aligos Therapeutics Inc
12 Mar 24
Registration of securities for employees
4:51pm
Employee Stock Purchase Plan
(Full Title of the Plan)
Lawrence M. Blatt, Ph.D.
President and Chief Executive Officer
Aligos Therapeutics, Inc.
One … to eligible employees of the Registrant under the Registrant’s 2020 Employee Stock Purchase Plan (the “ESPP”). Shares available for issuance under
S-8
jx61k
12 Mar 24
Registration of securities for employees
4:51pm
S-8
EX-5.1
613fi224
12 Mar 24
Registration of securities for employees
4:51pm
S-8
EX-23.2
u8op7
12 Mar 24
Registration of securities for employees
4:51pm
SC TO-I
EX-99
6rrwtk1sjyu
30 Jan 24
Issuer tender offer statement
7:04am
SC TO-I
EX-99
rhwap66y 7efjo33jdk8
30 Jan 24
Issuer tender offer statement
7:04am
SC TO-I
EX-99
h0v91ayd
30 Jan 24
Issuer tender offer statement
7:04am
SC TO-I
EX-99
ze4id
30 Jan 24
Issuer tender offer statement
7:04am
SC TO-I
EX-99
vsw3f7mi
30 Jan 24
Issuer tender offer statement
7:04am
SC TO-I
EX-99
d2uk 0iwzadguk8
30 Jan 24
Issuer tender offer statement
7:04am
SC TO-I
EX-99
9p450rx
30 Jan 24
Issuer tender offer statement
7:04am